13,551 Shares of AtriCure, Inc. $ATRC Purchased by Yousif Capital Management LLC

Yousif Capital Management LLC purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 13,551 shares of the medical device company’s stock, valued at approximately $762,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ATRC. Net Worth Advisory Group acquired a new position in AtriCure during the third quarter valued at $305,000. State of Alaska Department of Revenue grew its holdings in AtriCure by 265.6% in the third quarter. State of Alaska Department of Revenue now owns 10,497 shares of the medical device company’s stock valued at $589,000 after purchasing an additional 7,626 shares during the period. NorthCrest Asset Manangement LLC purchased a new stake in AtriCure in the 3rd quarter worth $298,000. Moody National Bank Trust Division acquired a new position in AtriCure during the third quarter worth $215,000. Finally, Tidal Investments LLC lifted its holdings in AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after purchasing an additional 6,034 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Price Performance

ATRC stock opened at $59.88 on Tuesday. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $63.00. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $3.05 billion, a P/E ratio of 267.04 and a beta of 1.24. The business has a 50 day simple moving average of $55.80 and a 200-day simple moving average of $38.28.

Insider Activity

In other news, insider Karl S. Dahlquist sold 9,370 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This trade represents a 9.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 37,686 shares of company stock valued at $1,898,756 over the last ninety days. 4.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ATRC has been the subject of a number of research reports. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Freedom Capital lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a research note on Wednesday, October 21st. Finally, Piper Sandler raised their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $55.70.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.